Latest News on SLP

Financial News Based On Company


Advertisement
Advertisement

Simulations Plus, Inc. SEC Filing (Oct 16, 2026)

https://www.stocktitan.net/sec-filings/SLP/15-12g-simulations-plus-inc-sec-filing-009919f825bb.html
Simulations Plus, Inc. filed a Form 15 with the SEC on October 16, 2026, certifying the termination of its registration under Section 12(g) and suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing indicates the company has only one holder of record. This action follows recent news of the company's acquisition by Altaris, which was completed on October 6, 2026.

Simulations Plus completes USD 376.8 million merger, taking Simulations Plus stock private

https://www.ad-hoc-news.de/boerse/news/nebenwerte/simulations-plus-completes-usd-376-8-million-merger-taking-simulations-plus-stock-private/70334846
Simulations Plus completed a USD 376.8 million merger on October 6, 2026, becoming a privately held subsidiary of an Altaris affiliate. Shareholders received USD 18.50 per share, and the company's stock was delisted from Nasdaq. The merger combines Simulations Plus with Chemical Computing Group, aiming to integrate drug discovery, modeling, simulation, and development platforms.

Simulations Plus completes USD 376.8 million merger, taking Simulations Plus stock private

https://www.ad-hoc-news.de/boerse/news/nebenwerte/simulations-plus-completes-usd-376-8-million-merger-taking-simulations/70334846
Simulations Plus has completed a USD 376.8 million merger, resulting in the company going private and its stock delisted from Nasdaq. Shareholders received USD 18.50 per share in cash as part of the deal, which makes Simulations Plus a wholly owned subsidiary of an Altaris affiliate. The company will continue its operations in model-informed drug development, pharmacometrics, toxicology, and AI-enabled drug design, now combined with Chemical Computing Group under private ownership.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

https://supplychaindigital.com/globenewswire/3378247
Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) after the company cut its fiscal 2025 revenue guidance and disclosed a significant net loss including an impairment charge. These issues, along with the dismissal of its independent accounting firm, Grant Thornton LLP, which cited unresolved concerns about reporting and internal controls, led to substantial declines in Simulations Plus shares. The investigation aims to determine if investors who suffered losses can recover them under federal securities laws.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

https://www.globenewswire.com/news-release/2026/10/09/3378247/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) after the company cut its fiscal 2025 revenue guidance and disclosed a significant net loss including an impairment charge. Further concerns arose when their accounting firm, Grant Thornton LLP, was dismissed and reported unresolved issues regarding financial reporting. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
Advertisement

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

https://www.biospace.com/press-releases/simulations-plus-announces-funded-partnership-with-global-pharmaceutical-company-to-advance-ai-enabled-qsp-model-development-with-turin
Simulations Plus, Inc. has announced a funded partnership with a global pharmaceutical company to integrate its AI-enabled quantitative systems pharmacology (QSP) engine, Turin, into an active therapeutic development program. This collaboration aims to significantly reduce the time and expertise traditionally required for QSP model development by using AI to explore mechanistic model structures at scale. The partnership combines AI computational exploration with expert human scientific judgment to accelerate drug development decisions.

Simulations Plus, Inc. SEC Filing (Oct 8, 2026)

https://www.stocktitan.net/sec-filings/SLP/effect-simulations-plus-inc-sec-filing-2366a5d02269.html
This article reports on an SEC filing by Simulations Plus, Inc. (SLP) which became effective on October 7, 2026. The filing is a Notice of Effectiveness with Accession Number 0001023459-26-000096 and Submission Type POS AM. The article also provides recent news and SEC filings related to Simulations Plus, Inc., including its market capitalization and other stock data.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

https://www.01net.it/simulations-plus-announces-funded-partnership-with-global-pharmaceutical-company-to-advance-ai-enabled-qsp-model-development-with-turin/
Simulations Plus has announced a funded partnership with a global pharmaceutical company to integrate Turin, its AI-enabled scientific engine, into an active therapeutic development program. This collaboration aims to use AI to significantly reduce the time and expertise required for quantitative systems pharmacology (QSP) model development and evaluation. By combining AI-scale computational exploration with human scientific judgment, the partnership seeks to make QSP models more practical and broadly applicable in drug development.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

https://www.lelezard.com/en/news-simulations-plus-announces-funded-partnership-with-global-pharmaceutical-company-to-advance-ai-22395603.html
Simulations Plus (Nasdaq: SLP) has partnered with a global pharmaceutical company to integrate its AI-enabled scientific engine, Turin, into a therapeutic development program. This collaboration aims to use AI to streamline QSP model building and evaluation, making it more accessible for drug development. The initiative seeks to overcome traditional limitations in QSP by systematically exploring and evaluating mechanistic model structures, thereby reducing development time and enhancing practical utility.

Simulations Plus Announced Transfer or Voluntary Withdrawal of Listing

https://www.tradingview.com/news/tradingview:0cb6346052904:0-simulations-plus-announced-transfer-or-voluntary-withdrawal-of-listing/
Simulations Plus (SLP) has announced its delisting from Nasdaq following the completion of its merger on October 6, 2026. The company requested cessation of trading and suspension of listing, and also intends to file Form 15 to terminate registration and suspend reporting obligations. Its shares are no longer listed on Nasdaq as of that date.
Advertisement

9,300 options were canceled without payment as Simulations Plus (SLP) revenue chief disposed of shares.

https://www.stocktitan.net/sec-filings/SLP/form-4-simulations-plus-inc-insider-trading-activity-988e5e9eed9f.html
Simulations Plus (SLP) Chief Revenue Officer John Anthony DiBella II disposed of 85,140 common shares on October 6, 2026, as part of a merger agreement where each share converted to $18.50 in cash. His stock options were also impacted; those with exercise prices below $18.50 converted to cash, while 9,300 options with exercise prices equal to or greater than $18.50 were canceled without payment. This transaction resulted in DiBella II holding zero common shares and zero stock options in the company.

Simulations Plus' (SLP) "Neutral" Rating Reaffirmed at BTIG Research

https://www.marketbeat.com/instant-alerts/analyst-simulations-plus-slp-neutral-rating-reaffirmed-at-btig-research-2026-10-07/
BTIG Research has reaffirmed its "neutral" rating for Simulations Plus (SLP), aligning with a general cautious sentiment among analysts, resulting in a consensus "Reduce" rating and an average price target of $17.25. Despite this, Simulations Plus reported strong quarterly results, with adjusted earnings of $0.30 per share and revenue of $21.89 million, both exceeding analyst expectations. The company's stock opened at $18.50, and institutional investors hold approximately 78.08% of its outstanding shares.

News On Simulations Plus Inc. (SLP) Now Under ALTA.XX

https://www.moomoo.com/news/post/1000665923/news-on-simulations-plus-inc-slp-now-under-altaxx
This article announces that news regarding Simulations Plus Inc. (SLP) is now being published under the ticker ALTA.XX. The content of the article itself is not available in the provided text, only this brief announcement.

Sharlene Evans Sells 17,173 Shares of Simulations Plus in $18.50 Per Share Merger Deal

https://kalkinemedia.com/us/news/announcements/sharlene-evans-sells-17173-shares-of-simulations-plus-in-1850-per-share-merger-deal
Sharlene Evans, a Director at Simulations Plus, Inc. (NASDAQ:SLP), sold 17,173 shares of the company's common stock on October 6, 2026, as part of a merger deal. The shares were sold for $18.50 cash per share, resulting in Evans having zero beneficial ownership in the company post-transaction. This sale was conducted under the terms of an Agreement and Plan of Merger dated June 15, 2026, where SP Evolution BidCo II, LLC merged into Simulations Plus, Inc.

After its October 6 merger, Simulations Plus (SLP) ends offerings under its 1999 stock registration.

https://www.stocktitan.net/sec-filings/SLP/pos-am-simulations-plus-inc-sec-filing-3805f35e604f.html
Simulations Plus (SLP) has terminated its 1999 Form S-3 registration statement, which covered up to 530,000 shares of common stock, following its merger on October 6, 2026. The merger made Simulations Plus a wholly owned subsidiary of SP Evolution HoldCo II, LLC. Consequently, the company has removed all unsold or unissued securities from registration.
Advertisement

Form 4 Simulations Plus Inc For: 6 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-simulations-plus-inc-for-6-october-93CH-4868524
This article reports on a Form 4 filing for Simulations Plus Inc. on October 6, 2026. The content provides a brief notification of the filing without further details about the transaction itself. It highlights the company's stock symbol SLP and includes a general market data overview.

Press Release: Simulations Plus Announces Completion of Acquisition by Altaris

https://news.futunn.com/en/post/1000619104/press-release-simulations-plus-announces-completion-of-acquisition-by-altaris
Simulations Plus has announced the completion of its acquisition by Altaris, a healthcare investment firm. This move takes Simulations Plus private, concluding its 28-year run as a publicly traded company. The acquisition is expected to support the company's continued growth and innovation in the biosimulation software and services sector.

Jill Fiedler-Kelly’s Simulations Plus (SLP) shares convert to $18.50-per-share cash rights in merger.

https://www.stocktitan.net/sec-filings/SLP/form-4-simulations-plus-inc-insider-trading-activity-c14d50c5a77b.html
Jill Fiedler-Kelly, President, Services Solutions of Simulations Plus, Inc. (SLP), reported disposition transactions wherein 77,817 common shares were converted into a right to receive $18.50 per share in cash due to a merger. Her direct common-stock holdings are now zero, and a 27,500-share option at $16.02 converted to a cash right, while other options at or above the merger consideration were canceled without payment. This Form 4 filing details the merger's impact on her equity and options.

Simulations Plus appoints Paul Labute as President; Matteo Foderaro and Charles Mullens join board

https://www.tradingview.com/news/tradingview:4061d458896ce:0-simulations-plus-appoints-paul-labute-as-president-matteo-foderaro-and-charles-mullens-join-board/
Simulations Plus has appointed Paul Labute as its new President following a merger. Additionally, Matteo Foderaro and Charles Mullens have joined the board of directors, while four previous directors have ceased their service. These changes are effective as of October 6, 2026, and are in accordance with the merger agreement.

Form 4 Simulations Plus, Inc. For: Oct 06 Filed by: OCONNOR SHAWN

https://www.streetinsider.com/SEC+Filings/Form+4+Simulations+Plus%2C+Inc.+For%3A+Oct+06+Filed+by%3A+OCONNOR+SHAWN/27155373.html
This Form 4 filing details changes in beneficial ownership for Shawn O'Connor, CEO of Simulations Plus, Inc. (SLP), related to the company's merger. The report indicates the disposition of various stock options due to the merger agreement, where options were either cashed out or canceled if their exercise price was at or above the merger consideration of $18.50 per share.
Advertisement

Form 25-NSE Simulations Plus, Inc. Filed by: Nasdaq Stock Market LLC

https://www.streetinsider.com/SEC+Filings/Form+25-NSE+Simulations+Plus%2C+Inc.+Filed+by%3A+Nasdaq+Stock+Market+LLC/27154769.html
This article reports on the filing of Form 25-NSE by Nasdaq Stock Market LLC concerning Simulations Plus, Inc. The filing is a standard SEC document related to the delisting of securities. The article itself is very brief, mainly serving as an alert for the filing.

Altaris Completes Simulations Plus Acquisition, Combines Company With Chemical Computing Group

https://www.citybiz.co/article/914863/altaris-completes-simulations-plus-acquisition-combines-company-with-chemical-computing-group/
Altaris has completed its acquisition of Simulations Plus Inc. for $18.50 per share in cash, taking the drug development software company private. Simulations Plus will be combined with Altaris's portfolio company Chemical Computing Group (CCG) to create a broader pharmaceutical research and development technology platform. This merger will integrate complementary software and scientific capabilities, aiming to serve biopharmaceutical customers across more stages of the drug development lifecycle and accelerate innovation in AI-supported pharmaceutical R&D.

Altaris, LLC completed the acquisition of Simulations Plus, Inc. from Walter Woltosz, Virginia Woltosz and others.

https://www.marketscreener.com/news/altaris-llc-completed-the-acquisition-of-simulations-plus-inc-from-walter-woltosz-virginia-wolto-ce785dd9da88f223
Altaris, LLC has completed its acquisition of Simulations Plus, Inc. for approximately $370 million. As a result, Simulations Plus will become a privately held subsidiary of Altaris, and its stock will no longer be traded on the Nasdaq Stock Exchange. The transaction received unanimous approval from the Simulations Plus Board of Directors and shareholder approval, with plans to combine Simulations Plus with Chemical Computing Group.

Simulations Plus Announces Completion of Acquisition by Altaris

https://finance.yahoo.com/healthcare/articles/simulations-plus-announces-completion-acquisition-131500106.html
Simulations Plus, a leader in model-informed and AI-accelerated drug development, announced the completion of its acquisition by Altaris, an investment firm focused on healthcare. Shareholders received $18.50 per share in cash, and the company will now operate privately, combining with Altaris portfolio company Chemical Computing Group (CCG) to create a broader platform for drug discovery and development. The merger aims to accelerate innovation and expand services within the biopharmaceutical research and development lifecycle.

Eight analysts rate Simulations Plus stock Reduce

https://www.ad-hoc-news.de/boerse/news/nebenwerte/eight-analysts-rate-simulations-plus-stock-reduce/70236899
Eight brokerages have given Simulations Plus (SLP) an average "Reduce" rating with a 12-month target of USD 17.25, according to a MarketBeat report on September 25, 2026. This target is below the reported opening price of USD 18.46, despite the company exceeding revenue expectations in its fiscal third quarter 2026. The FDA's recent licensing of ADMET Predictor for computational safety research further highlights the company's expanding market beyond traditional pharmaceutical applications.
Advertisement

Simulations Plus Announces Completion of Acquisition by Altaris

https://ca.finance.yahoo.com/news/simulations-plus-announces-completion-acquisition-131500106.html
Simulations Plus, a leader in model-informed and AI-accelerated drug development, has completed its acquisition by affiliates of Altaris, LLC. The transaction, originally announced on June 16, 2026, results in Simulations Plus becoming a privately held company and its stock no longer trading on Nasdaq. It will combine with Chemical Computing Group (CCG), an Altaris portfolio company, to create a broader platform spanning drug discovery, modeling, simulation, and development, while Simulations Plus will retain its name and brand.

Simulations Plus, Inc.(NasdaqGS: SLP) dropped from S&P TMI Index

https://www.marketscreener.com/news/simulations-plus-inc-nasdaqgs-slp-dropped-from-s-p-tmi-index-ce785dd8dd80fe26
Simulations Plus, Inc. (NasdaqGS:SLP) has been removed from the S&P TMI Index, according to an announcement published on October 5, 2026, at 09:08 pm EDT. This news follows a similar report indicating its removal from the S&P Global BMI Index. The company specializes in model-informed and AI-accelerated drug development, offering software and consulting solutions to the pharmaceutical sector.

Simulations Plus stock faces October 5 trading deadline

https://www.ad-hoc-news.de/boerse/news/corporate-news/simulations-plus-stock-faces-october-5-trading-deadline/70225294
Simulations Plus (SLP) stock is set for its last trading day on October 5, 2026, ahead of its merger with affiliates of Altaris, LLC, with shareholders receiving USD 18.50 per share. Despite a recent 7% revenue increase and improved gross margins, the stock's current price aligns with the cash offer, not conventional earnings. Analysts maintain a "Reduce" consensus with an average price target below the merger price.

95,805 Shares in Simulations Plus, Inc. $SLP Acquired by Bank of America Corp DE

https://www.marketbeat.com/instant-alerts/filing-95805-shares-in-simulations-plus-inc-slp-acquired-by-bank-of-america-corp-de-2026-10-02/
Bank of America Corp DE has acquired 95,805 shares of Simulations Plus, Inc. (NASDAQ:SLP) during the second quarter, valued at approximately $1.75 million. This acquisition makes Bank of America a significant institutional holder, with 0.47% of the company's stock, contributing to the 78.08% institutional ownership. Despite Simulations Plus beating earnings estimates with an EPS of $0.30 and revenue of $21.89 million, analysts largely maintain a "Hold" rating, with an average price target below its current trading price.

Form DEF 14A Simulations Plus Inc For: 1 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-def-14a-simulations-plus-inc-for-1-october-93CH-4861459
Investing.com reports on Simulations Plus Inc.'s (SLP) DEF 14A filing for October 1. The article provides the title of the SEC filing and notes that the stock symbol SLP was up 0.33%.
Advertisement

Form DEF 14A Simulations Plus Inc For: 1 October

https://in.investing.com/news/stock-market-news/form-def-14a-simulations-plus-inc-for-1-october-93CH-5614259
This article announces the filing of Form DEF 14A by Simulations Plus Inc. on October 1st. It provides no further details about the content of the filing, serving primarily as a brief notification of the regulatory document. The article is published by Investing.com.

Simulations Plus, Inc. (NASDAQ:SLP) Receives Average Rating of "Reduce" from Analysts

https://www.marketbeat.com/instant-alerts/consensus-simulations-plus-inc-nasdaq-slp-receives-average-rating-of-reduce-from-analysts-2026-09-25/
Simulations Plus, Inc. (NASDAQ:SLP) has received an average "Reduce" rating from eight brokerages, with an average 12-month price target of $17.25, below its current trading price. This cautious analyst sentiment comes despite the company exceeding quarterly earnings and revenue expectations. Institutional investors hold a significant 78.08% stake, while insiders own 19.10%, with a recent director sale noted under a pre-arranged trading plan.

Simulations Plus (NASDAQ:SLP) Stock Crosses Above 200-Day Moving Average - Here's What Happened

https://www.marketbeat.com/instant-alerts/price-simulations-plus-nasdaq-slp-stock-crosses-above-200-day-moving-average-heres-what-happened-2026-09-24/
Simulations Plus (NASDAQ:SLP) shares recently crossed above their 200-day moving average, reaching $18.42, well above the $16.21 average. The company also surpassed quarterly earnings expectations, reporting an EPS of $0.30 against an estimate of $0.23 and revenue of $21.89 million against a $20.90 million consensus. Despite this, analyst sentiment remains cautious with a consensus "Reduce" rating and an average price target of $17.25.

Simulations Plus Says FDA's Cosmetics Branch Adopts ADMET Predictor

https://finance.yahoo.com/technology/ai/articles/simulations-plus-says-fda-apos-084325040.html
Simulations Plus (SLP) announced that the US Food and Drug Administration's cosmetics branch has adopted its ADMET Predictor software. The article, however, appears to be a premium content piece, requiring a subscription for full access.

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

https://finance.yahoo.com/healthcare/articles/simulations-plus-expands-fda-adoption-214500541.html
Simulations Plus, Inc. announced that the U.S. FDA's Cosmetics Regulatory Science Branch has licensed its ADMET Predictor® platform to support modern cosmetic safety assessment through integrated exposure and toxicity modeling. This expansion underscores the growing importance of predictive modeling and mechanistic science in regulatory research and reflects the versatility of Simulations Plus' technology beyond pharmaceuticals. The platform provides advanced AI/ML technology, novel descriptors, and predictive models to rapidly assess endpoint properties and systemic exposure.
Advertisement

Simulations Plus, Inc. Expands FDA Adoption Of ADMET Predictor With New Licenses For The Cosmetics Regulatory Science Branch

https://www.marketscreener.com/news/simulations-plus-inc-expands-fda-adoption-of-admet-predictor-with-new-licenses-for-the-cosmetics-r-ce785bd3d08cf225
Simulations Plus, Inc. announced that the U.S. FDA's Cosmetics Regulatory Science Branch has licensed its ADMET Predictor platform. This expansion supports the FDA's computational research for modern cosmetic safety assessment by leveraging advanced AI and machine learning technology for predictive modeling. The platform helps evaluate potential exposure and intrinsic hazards, aligning with the FDA's research into New Approach Methodologies and reinforcing Simulations Plus's role in predictive science across regulated industries.

Squarepoint Ops LLC Sells 58,282 Shares of Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-sells-58282-shares-of-simulations-plus-inc-slp-2026-09-16/
Squarepoint Ops LLC reduced its stake in Simulations Plus, Inc. by 40.8% in Q2, selling 58,282 shares and retaining 84,655 shares valued at $1.55 million. The company's stock has a consensus "Reduce" rating and an average price target of $17.25 from analysts. Despite analyst caution and a stock drop, Simulations Plus exceeded quarterly earnings expectations, reporting $0.30 EPS against an estimated $0.23, and revenue of $21.89 million compared to $20.90 million estimated.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

https://www.globenewswire.com/news-release/2026/09/10/3359750/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) after the company cut its fiscal 2025 revenue guidance and experienced significant stock declines. Further concerns arose following a large net loss, an impairment charge, and the dismissal of its accounting firm, which cited unresolved issues regarding financial reporting. The law firm is seeking to connect with investors who suffered losses to explore potential claims under federal securities laws.

First Light Asset Management LLC Raises Position in Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-first-light-asset-management-llc-raises-position-in-simulations-plus-inc-slp-2026-09-10/
First Light Asset Management LLC significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 6.1% in the second quarter, now holding 2.79 million shares valued at approximately $51.1 million, representing 13.81% of the company. Despite positive quarterly earnings that beat analyst expectations, the stock's performance has been cautious, with analysts maintaining a "Reduce" rating and a consensus price target below the current share price. Other institutional investors also adjusted their positions, and a director sold shares in July.

Bank of New York Mellon Corp Takes $1.25 Million Position in Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-125-million-position-in-simulations-plus-inc-slp-2026-09-10/
Bank of New York Mellon Corp has acquired a new stake of 68,095 shares, valued at approximately $1.25 million, in Simulations Plus, Inc. This purchase makes them owners of about 0.34% of the company, with institutional investors collectively holding 78.08% of the stock. Despite the institutional interest, analyst sentiment has weakened, leading to several downgrades to "hold" or "market perform" ratings, with an average target price of $17.25. Simulations Plus recently exceeded quarterly earnings expectations, reporting $0.30 EPS against a $0.23 consensus and revenues of $21.89 million against $20.90 million expected.
Advertisement

Groupe la Francaise Acquires Shares of 127,200 Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-groupe-la-francaise-acquires-shares-of-127200-simulations-plus-inc-slp-2026-09-08/
Groupe la Francaise acquired 127,200 shares of Simulations Plus, Inc. (NASDAQ:SLP) in the second quarter, valued at approximately $2.33 million, representing about 0.63% of the company. Despite Simulations Plus exceeding quarterly earnings and revenue expectations, analyst sentiment has weakened, leading to several downgrades to "Hold" or "Market Perform" and a consensus "Reduce" rating with an average price target of $17.25. Insider activity also noted a director selling over 4,000 shares in July.

Simulations Plus (NASDAQ:SLP) Beats Estimates Despite Caution

https://kalkinemedia.com/us/stocks/healthcare/simulations-plus-nasdaqslp-beats-estimates-despite-caution
Simulations Plus (NASDAQ:SLP) exceeded earnings and revenue estimates in its latest quarter, driven by demand for its specialized scientific modeling and simulation software in the pharmaceutical industry. Despite the strong operational performance, analyst sentiment remains cautious due to the company's elevated valuation and concerns about sustained growth. The article highlights the balancing act between the company's valuable offerings in healthcare technology and market expectations embedded in its stock price.

Simulations Plus, Inc. (NASDAQ:SLP) Given Consensus Recommendation of "Reduce" by Analysts

https://www.marketbeat.com/instant-alerts/consensus-simulations-plus-inc-nasdaq-slp-given-consensus-recommendation-of-reduce-by-analysts-2026-08-31/
Analysts have assigned Simulations Plus, Inc. (NASDAQ:SLP) a consensus "Reduce" recommendation, with an average 12-month price target of $17.25, below its recent trading price of $18.39. Despite the cautious outlook, the company surpassed quarterly expectations with EPS of $0.30 and revenue of $21.89 million. Insider activity shows Director Walter S. Woltosz selling a small portion of his shares, while institutional investors and hedge funds collectively hold a significant stake in the company.

Meros Investment Management LP Makes New $2.38 Billion Investment in Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-meros-investment-management-lp-makes-new-238-billion-investment-in-simulations-plus-inc-slp-2026-08-26/
Meros Investment Management LP has acquired a new stake worth approximately $2.38 billion in Simulations Plus, Inc. (NASDAQ:SLP) during the second quarter, representing 0.64% of the company's stock. Other institutional investors like Royal Bank of Canada and Rhumbline Advisers also increased their positions in SLP. Simulations Plus recently reported strong Q2 earnings, beating analyst estimates, but its stock traded down by 0.1% on Wednesday.

127,874 Shares in Simulations Plus, Inc. $SLP Acquired by Polar Asset Management Partners Inc.

https://www.marketbeat.com/instant-alerts/filing-127874-shares-in-simulations-plus-inc-slp-acquired-by-polar-asset-management-partners-inc-2026-08-26/
Polar Asset Management Partners Inc. acquired a new position of 127,874 shares in Simulations Plus, Inc. (NASDAQ:SLP) valued at approximately $2.34 million during the 2nd quarter. Institutional investors and hedge funds now own 78.08% of the company's stock. Despite beating quarterly earnings expectations, analyst sentiment is cautious, with a consensus "Reduce" rating and a target price of $17.25.
Advertisement

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

https://www.globenewswire.com/news-release/2026/08/20/3348549/0/en/johnson-fistel-investigates-simulations-plus-following-revenue-guidance-cut-and-accounting-disclosures.html
Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses following a significant revenue guidance cut, preliminary third-quarter revenue results, and subsequent decline in share value. Further concerns arose after a large net loss, a non-cash impairment charge, and the dismissal of their independent accounting firm, Grant Thornton LLP, which cited unresolved issues regarding segment reporting and internal controls. The firm is encouraging affected investors to contact them for more information regarding the investigation.

Rice Hall James & Associates LLC Purchases Shares of 103,010 Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-rice-hall-james-associates-llc-purchases-shares-of-103010-simulations-plus-inc-slp-2026-08-19/
Rice Hall James & Associates LLC recently acquired 103,010 shares of Simulations Plus, Inc. (NASDAQ:SLP) worth approximately $1.89 million, representing 0.51% of the company. Institutional investors now own 78.08% of the stock. Despite the institutional interest, analysts maintain a "Reduce" rating for Simulations Plus, with an average price target of $17.25, even though the company recently surpassed quarterly earnings and revenue expectations.

Simulations Plus (NASDAQ:SLP): What Is Driving the Debate?

https://kalkinemedia.com/us/stocks/healthcare/simulations-plus-nasdaqslp-what-is-driving-the-debate
Simulations Plus (NASDAQ:SLP) is experiencing increased market caution despite stronger-than-expected quarterly results, highlighting a disconnect between operational performance and investor sentiment. The company, which specializes in pharmaceutical modeling and simulation software, benefits from growing demand for digital tools in drug development. Valuation concerns and future growth expectations are key factors contributing to the market's cautious stance, even as institutional activity shows continued interest in the stock.

Short Interest in Simulations Plus, Inc. (NASDAQ:SLP) Grows By 59.7%

https://www.marketbeat.com/instant-alerts/short-interest-in-simulations-plus-inc-nasdaqslp-grows-by-597-2026-08-18/
Short interest in Simulations Plus, Inc. (NASDAQ:SLP) increased by 59.7% in July, reaching 2.84 million shares, which represents 17.4% of outstanding shares and a 5.2 days-to-cover ratio. This surge in short interest comes amidst weakening analyst sentiment, with several firms downgrading the stock to "Hold" or "Market Perform," resulting in a consensus "Reduce" rating and an average price target of $17.25. Despite this bearish trend, the company exceeded quarterly expectations with $0.30 EPS and $21.89 million in revenue.

Quantinno Capital Management LP Boosts Stock Holdings in Simulations Plus, Inc. $SLP

https://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-boosts-stock-holdings-in-simulations-plus-inc-slp-2026-08-14/
Quantinno Capital Management LP significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 439.1% in the first quarter, now holding 112,259 shares valued at $1.33 million. Despite this, analyst sentiment remains cautious with an average "Reduce" rating and a $17.25 price target, even though the company exceeded its recent quarterly earnings and revenue expectations. Institutional investors and hedge funds collectively own 78.08% of the company's stock.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement